ReviewJID innovations : skin science from molecules to population health2026
Immune shifts in inflammatory skin diseases.
Review in JID innovations : skin science from molecules to population health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory skin diseases are driven by dominant immune programs, including T helper (Th)1, Th2, Th17, type I IFN, and neutrophilic pathways, which shape responsiveness to targeted immunotherapies. Molecular profiling has revealed that these diseases frequently harbor additional, coexisting immune programs and that dominance among pathways can shift over time, either spontaneously or in response to therapy. Such immune shifts, which limit therapeutic effectiveness, often occur in the absence of clinically evident morphological changes. In this review, we describe the molecular immune landscape of inflammatory skin diseases, with an emphasis on psoriasis and atopic dermatitis, and illustrate the immune shifts that underlie therapy-resistant disease states and paradoxical reactions. We propose a model of an immune continuum governed by a dynamic equilibrium among inflammatory pathways that is susceptible to displacement. Finally, we highlight molecular immune profiling as a critical tool for detecting such shifts and enabling rational therapeutic adaptation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.